Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
16.9M
-
Shares change
-
+3.5M
-
Total reported value, excl. options
-
$41.8M
-
Value change
-
+$8.59M
-
Put/Call ratio
-
1.3
-
Number of buys
-
34
-
Number of sells
-
-9
-
Price
-
$2.47
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q1 2021
59 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q1 2021.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.9M shares
of 77M outstanding shares and own 22% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.21M shares), Carmignac Gestion (3.54M shares), VANGUARD GROUP INC (1.73M shares), ACUTA CAPITAL PARTNERS, LLC (1.61M shares), BlackRock Inc. (873K shares), TWO SIGMA INVESTMENTS, LP (722K shares), TWO SIGMA ADVISERS, LP (652K shares), RENAISSANCE TECHNOLOGIES LLC (564K shares), GEODE CAPITAL MANAGEMENT, LLC (365K shares), and MORGAN STANLEY (359K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.